See more : St. Galler Kantonalbank AG (SGKN.SW) Income Statement Analysis – Financial Results
Complete financial analysis of TRxADE HEALTH, Inc. (MEDS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TRxADE HEALTH, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
You may be interested
- Chimera Investment Corporation (CIM) Income Statement Analysis – Financial Results
- Organic Sales and Marketing, Inc. (OGSM) Income Statement Analysis – Financial Results
- Miquel y Costas & Miquel, S.A. (MCM.MC) Income Statement Analysis – Financial Results
- Vanta Bioscience Limited (VANTABIO.BO) Income Statement Analysis – Financial Results
- Archidply Industries Limited (ARCHIDPLY.NS) Income Statement Analysis – Financial Results
TRxADE HEALTH, Inc. (MEDS)
About TRxADE HEALTH, Inc.
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.27M | 11.45M | 9.89M | 17.12M | 7.44M | 3.83M | 2.93M | 2.48M | 4.99M | 1.50M | 955.88K | 806.05K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.67M | 6.00M | 5.14M | 11.42M | 2.57M | 449.05K | 0.00 | 16.36K | 1.93M | 440.05K | 944.07K | 689.81K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.60M | 5.45M | 4.75M | 5.71M | 4.87M | 3.38M | 2.93M | 2.47M | 3.06M | 1.06M | 11.81K | 116.24K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 31.41% | 47.62% | 47.99% | 33.33% | 65.50% | 88.28% | 100.00% | 99.34% | 61.38% | 70.59% | 1.24% | 14.42% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.38M | 1.16M | 1.37M | 662.73K | 647.14K | 949.95K | 375.17K | 286.76K | 319.44K | 319.44K | 611.71K | 198.41K | 0.00 | 0.00 | 3.57K |
| General & Administrative | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.30M | 3.70M | 2.11M | 2.10M | 266.95K | 28.50M | 0.00 | 5.16K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.63K | 355.12K | 374.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.48M | 7.05M | 8.81M | 7.49M | 4.38M | 2.35M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 24.77K | 5.16K |
| Other Expenses | 14.54K | 1.60M | -1.23M | 3.25M | 72.08K | 161.64K | 67.50K | 131.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.42K | 0.00 |
| Operating Expenses | 9.86M | 8.21M | 8.81M | 7.49M | 4.38M | 3.30M | 2.27M | 3.45M | 4.05M | 2.49M | 2.10M | 266.95K | 28.50M | 28.19K | 8.73K |
| Cost & Expenses | 15.54M | 14.20M | 13.96M | 18.90M | 6.94M | 3.75M | 2.27M | 3.47M | 5.98M | 2.93M | 3.04M | 956.76K | 28.50M | 28.19K | 8.73K |
| Interest Income | 4.20K | 20.99K | 23.59K | 29.39K | 53.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.20M | 336.21K | 23.59K | 29.39K | 53.23K | 57.54K | 157.06K | 151.50K | 130.14K | 4.15K | 7.28K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.05M | 194.70K | 138.91K | 102.52K | 94.73K | 87.62K | -395.10K | 8.67K | 3.80K | 4.80K | 3.99K | 2.63K | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.72M | -1.85M | -5.15M | -2.51M | 660.55K | 96.65K | 288.98K | -984.03K | -133.27K | -2.00M | -2.08M | -148.09K | -28.50M | -28.19K | -8.73K |
| EBITDA Ratio | -74.89% | -22.18% | -52.11% | -9.80% | 8.88% | 6.36% | 24.92% | -39.65% | -19.70% | -95.35% | -217.60% | -18.37% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.26M | -2.76M | -5.29M | -1.78M | 565.82K | -87.62K | 395.10K | -984.03K | -987.05K | -1.43M | -2.08M | -150.71K | -28.50M | -28.19K | -8.73K |
| Operating Income Ratio | -87.80% | -24.08% | -53.51% | -10.40% | 7.61% | -2.29% | 13.48% | -39.65% | -19.77% | -95.67% | -218.02% | -18.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.46M | -362.72K | -23.59K | -29.39K | -778.17K | 96.65K | -106.11K | -165.83K | -119.51K | -580.57K | -7.28K | 0.00 | 28.47M | 0.00 | 0.00 |
| Income Before Tax | -13.72M | -3.91M | -5.32M | -2.54M | -284.43K | 9.04K | 288.98K | -1.17M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50K | 0.00 | 0.00 |
| Income Before Tax Ratio | -165.86% | -34.15% | -53.75% | -14.81% | -3.82% | 0.24% | 9.86% | -47.27% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.34M | 400.34K | -1.20M | 29.39K | 125.30K | -154.20K | -50.94K | 1.62M | 130.14K | 576.42K | 7.28K | 0.00 | 28.50M | 28.19K | 8.73K |
| Net Income | -17.84M | -4.31M | -4.11M | -2.57M | -409.73K | 9.04K | 288.98K | -2.76M | -1.12M | -2.01M | -2.09M | -150.71K | -28.50M | -28.19K | -8.73K |
| Net Income Ratio | -215.70% | -37.65% | -41.59% | -14.98% | -5.51% | 0.24% | 9.86% | -111.21% | -22.38% | -134.47% | -218.78% | -18.70% | 0.00% | 0.00% | 0.00% |
| EPS | -23.35 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.89 | -3.20 | -6.30 | -13.50 | -0.97 | -273.59 | -0.27 | -0.11 |
| EPS Diluted | -7.49 | -7.63 | -7.58 | -4.99 | -1.04 | 0.02 | 0.81 | -7.87 | -3.20 | -6.07 | -13.35 | -0.97 | -269.45 | -0.27 | -0.11 |
| Weighted Avg Shares Out | 764.06K | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 355.06K | 349.64K | 349.64K | 319.37K | 154.91K | 154.91K | 104.16K | 105.76K | 81.20K |
| Weighted Avg Shares Out (Dil) | 2.38M | 564.86K | 542.45K | 513.71K | 395.27K | 388.43K | 378.74K | 350.50K | 349.64K | 331.46K | 156.69K | 154.91K | 105.76K | 105.76K | 81.20K |
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.
TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced that it is changing its name to Scienture Holdings, Inc. (“Scienture...
TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team
TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced the appointment of Narasimhan Mani, Ph.D., MBA as Scienture's President. Shankar...
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction valued at $103 million.
TRxADE Health, Inc. Announces Special Cash Dividend
TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (Nasdaq: MEDS) (the “Company”), announced that the Company's board of directors has declared a special cash dividend of $1.50 per share of common stock. The special dividend is being...
TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
TAMPA, FL, May 29, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (Nasdaq: MEDS) (the “Company”), announced that, on May 23, 2024, the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that because the Company...
TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
TAMPA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (Nasdaq: MEDS) (the “Company”), announced that, on April 17, 2024, the Company received a notice (the “Notice”) from the Nasdaq Listing Qualifications Department (“Nasdaq”) indicating that because the Company...
TRxADE Health, Inc. Announces Special Cash Dividend
TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (Nasdaq: MEDS) (the “Company”), announced that the Company's board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being...
Why Is Trxade Health (MEDS) Stock Up 230% Today?
Trxade Health (NASDAQ: MEDS ) stock is soaring higher on Tuesday after the U.S. health services IT company announced a major asset sale. According to a filing with the Securities and Exchange Commission (SEC), wholly-owned subsidiary Trxade, Inc. is going to...
Trxade health, Inc files its 3Q 10Q
TAMPA, FL, Jan. 17, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of pharmaceutical business-to-business exchange platform, announced today that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2023...
TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.
TAMPA, FL, Nov. 29, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE”), a parent company of a pharmaceutical business-to-business exchange platform, announced today that it received a notice of non-compliance from the Nasdaq Listing Qualifications Department (“Nasdaq”) on...
Source: https://incomestatements.info
Category: Stock Reports